Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) EPS (Weighted Average and Diluted) (2021 - 2025)

Spero Therapeutics (SPRO) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.13 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 59.38% year-over-year to -$0.13, compared with a TTM value of -$0.79 through Sep 2025, down 1087.5%, and an annual FY2024 reading of -$1.27, down 395.35% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.13 for Q3 2025 at Spero Therapeutics, down from -$0.03 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.97 in Q4 2023 and bottomed at -$1.01 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.27, with a median of -$0.29 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 201.09% in 2022, then plummeted 433.33% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.92 in 2021, then soared by 201.09% to $0.93 in 2022, then rose by 4.3% to $0.97 in 2023, then plummeted by 139.18% to -$0.38 in 2024, then soared by 65.79% to -$0.13 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SPRO at -$0.13 in Q3 2025, -$0.03 in Q2 2025, and -$0.25 in Q1 2025.